Details for Patent: 9,616,073

Title:	Method for on-demand contraception
Abstract:	The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-- dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Inventor(s):	Ulmann; Andre (Paris, FR), Gainer; Erin (Paris, FR), Mathe; Henri Camille (Paris, FR), Nieman; Lynnette (Bethesda, MD), Blithe; Diana (Silver Spring, MD)
Assignee:	Laboratoire HRA-Pharma (Paris, FR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Filing Date:	Apr 13, 2010
Application Number:	13/263,717
Claims:	1. A method for on-demand contraception, comprising the step of administering a unit dosage of 30 mg of ulipristal acetate to a woman by oral route within 120 hours after an intercourse, wherein the administration is at least twice during the woman's menstrual cycle wherein the at least twice administration is not on the same day and no more than 3 days in a row during the woman's menstrual cycle. 2. The method of claim 1, wherein ulipristal acetate is administered at least once a week during the menstrual cycle. 3. The method of claim 1, wherein ulipristal acetate is not administered more than two days in a row. 4. The method of claim 1 wherein ulipristal acetate is administered as a tablet.